Novartis study to compare Femara with AstraZeneca’s Arimidex

Share this article:
Novartis said it has initiated a study to compare its breast cancer drug Femara (letrozole) with AstraZeneca’s best-selling Arimidex (anastrozole), The Wall Street Journal reported. Novartis said the study will look at 4,000 patients around the world. It is the first trial that will compare the two medicines in use after breast cancer surgery. Last year Femara totaled $536 million in sales, compared with around $1.18 billion for Arimidex. AstraZeneca called the study a marketing move. A spokesperson for AstraZeneca told the Journal that the trial would be open-label, meaning that both doctors and patients will know which drugs are being used, unlike clinical studies required to obtain regulatory approval. “There is no scientific rationale for doing this,” the spokesperson said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.